Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01963793
Other study ID # LP0066-1019
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2013
Est. completion date July 2014

Study information

Verified date June 2021
Source LEO Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Topical Aprepitant in Prurigo Patients - An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patient with Prurigo suffering from chronic pruritus - Disease duration > six month - Therapy refractory to at least two previous antipruritic treatments with topical, intralesional or systemic corticosteroids, or other immunosuppressants, antihistamines, antipsychotics, antidepressants, anticonvulsants and/or UV-irradiation - Adult male or female patients, aged 18 to 80 years Exclusion Criteria: - Concomitant medications that are primarily metabolized through Cytochrome P450 3A4 - Applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin less than 3 weeks prior to Visit 1 (Screening) or during the course of the trial - UV-irradiation during the last 6 weeks prior to Visit 1 (Screening) - Prescribed systemic medications are limited - Clinically significant abnormalities in Blood analyses - Anamnestic excessive use of alcohol or tobacco or drugs - Presence of active tumor disease or history of malignancies within five years prior to Visit 1 (Screening) - Known or suspected hypersensitivity to component(s) of investigational products - Within the last 30 days or current participation in any other interventional clinical trial - Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the last 6 month - Previously enrolled/randomised in this clinical trial - In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state) - Females who are pregnant, of child-bearing potential and wishing to become pregnant during the trial or are breast feeding - Females of child-bearing potential with positive pregnancy test - Subjects (or their partner) not using an adequate method of contraception (according to national requirements, as applicable)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aprepitant
Aprepitant gel (10 mg/g)
Placebo
gel without active component

Locations

Country Name City State
Germany Allergie-Zentrum-Charité, Charité - Universitätsmedizin Berlin Berlin

Sponsors (1)

Lead Sponsor Collaborator
LEO Pharma

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pruritus by VAS (Visual Analogue Scale) At end of treatment (Day 28) participants assessed the intensity of present pruritus of each treated area on a visual analogue scale (VAS) with a score of "0" (no itch at all) to "10" (worst imaginable itch) at the two extremes on a 100 mm line. At end of treatment (Day 28)
Secondary Pruritus by VAS (Visual Analogue Scale) At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42, participants assessed the intensity of present pruritus of each treated area on a visual analogue scale (VAS) with a score of "0" (no itch at all) to "10" (worst imaginable itch) at the two extremes on a 100 mm line. At baseline (Day 1), Day 14, end of treatment (Day 28), and Day 42
Secondary Change From Baseline in Participants' Global Assessment on Treatment Areas At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42, participants assessed their prurigo on each treated area using the following score: 0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe. The change was calculated as the value at the later time point minus the value at baseline. The change at Day 1 was therefore 0 and negative values represent a decrease in score. At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Clinical Score Assessment of Crusting The (sub)investigator assessed the clinical picture at each treated area at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 using the following score:
Criteria:
Crusts
Evaluation:
0 = not existing
= mild
= moderate
= severe
The score will be an integer on the scale 0-3.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Clinical Score Assessment of Erythema The (sub)investigator will assess the clinical picture at each treated area at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 using the following score:
Criteria:
Erythema
Evaluation:
0 = not existing
= mild
= moderate
= severe
The score will be an integer on the scale 0-3.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Clinical Score Assessment of Scratch Artefacts The (sub)investigator will assess the clinical picture at each treated area at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 using the following score:
Criteria:
Scratch artefacts: Superficial damage to the skin caused by severe scratching.
Evaluation:
0 = not existing
= mild
= moderate
= severe
The score will be an integer on the scale 0-3.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Clinical Score Assessment of Infiltration The (sub)investigator will assess the clinical picture at each treated area at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 using the following score:
Criteria:
Infiltration
Evaluation:
0 = not existing
= mild
= moderate
= severe
The score will be an integer on the scale 0-3.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Transepidermal Water Loss (TEWL) The (sub)investigator will made the following clinical assessment:
Transepidermal water loss was defined as amount of released water from skin surface in g/cm^2 per hour. The TEWL is increased in case of damage of skin barrier.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Lesional Erythema by Mexameter The skin colour of the participants was evaluated by use of a Mexameter spectrophotometer. The instrument computed an erythema index (with a range between 0 and 999, where higher values indicate more erythema or redness) which may be used as an indication of skin properties.
Mexameter measurements were performed at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 to assess stimulation of microcirculation, irritating effects, and occurring erythema.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Non-lesional Erythema by Mexameter The skin colour of the participants was evaluated by use of a Mexameter spectrophotometer. The instrument computed an erythema index (with a range between 0 and 999, where higher values indicate more erythema or redness) which may be used as an indication of skin properties.
Mexameter measurements were performed at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 to assess stimulation of microcirculation, irritating effects, and occurring erythema.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Melanin by Mexameter The skin colour of the participants was evaluated by use of a Mexameter spectrophotometer. The instrument computed a melanin index (with a range between 0 and 999, where higher values indicate more melanin) which may be used as an indication of skin properties.
Mexameter measurements were performed at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 to assess stimulation of microcirculation, irritating effects, and occurring erythema.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Non-lesional Melanin by Mexameter The skin colour of the participants was evaluated by use of a Mexameter spectrophotometer. The instrument computed a melanin index (with a range between 0 and 999, where higher values indicate more melanin) which may be used as an indication of skin properties.
Mexameter measurements were performed at baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42 to assess stimulation of microcirculation, irritating effects, and occurring erythema.
At baseline (Day 1), Day 14, end of treatment (Day 28) and Day 42
Secondary Daily Assessments of Duration of Pruritus (Preceding 12 Hours) During the trial participants completed a diary twice daily, in the morning and in the evening, each covering the preceding 12 hours, which collected the number of hours with pruritus within the last 12 hours on both areas by use of a 7-point scale (<0.5 hours, 0.5-1 hours, 1-2 hours, 3-4 hours, 5-6 hours, 7-8 hours, 9-12 hours).
Duration of pruritus was categorized as follows: 1 if <0.5 hours, 2 if 0.5-1 hours, 3 if 1-2 hours, 4 if 3-4 hours, 5 if 5-6 hours, 6 if 7-8 hours and 7 if 9-12 hours.
The evening baseline measure was taken on the evening of Day -1 and the morning baseline measure was taken on the morning of Day 1 before cream was applied.
From baseline to Day 31
Secondary Daily Assessments of Average Pruritus by Use of a VAS During the trial participants completed a diary twice daily, in the morning and in the evening, each covering the preceding 12 hours, which collected the average intensity of pruritus since last evaluation by use of a VAS (ranging from 0 to 100). The participants assessed the intensity of present pruritus of each treated area on a visual analogue scale (VAS) with a score of "0" (no itch at all) to "10" (worst imaginable itch) at the two extremes on a 100 mm line.
The evening baseline measure was taken on the evening of Day -1 and the morning baseline measure was taken on the morning of Day 1, before cream was applied.
From baseline to Day 31
Secondary Daily Assessments of Maximum Intensity of Pruritus by Use of a VAS During the trial participants completed a diary twice daily, in the morning and in the evening, each covering the preceding 12 hours, which collected the maximum intensity of pruritus since last evaluation by use of a VAS (ranging from 0 to 100). The participants assessed the intensity of present pruritus of each treated area on a visual analogue scale (VAS) with a score of "0" (no itch at all) to "10" (worst imaginable itch) at the two extremes on a 100 mm line.
The evening baseline measure was taken on the evening of Day -1 and the morning baseline measure was taken on the morning of Day 1 before cream was applied.
From baseline to Day 31
Secondary Percent Change From Baseline in Pruritis Assessed by VAS at End of Treatment On the last day of treatment, participants assessed the change of pruritus compared to baseline in percentage by use of a VAS (ranging from 0 to 100). The participants assessed the intensity of present pruritus of each treated area on a visual analogue scale (VAS) with a score of "0" (no itch at all) to "10" (worst imaginable itch) at the two extremes on a 100 mm line. Day 28
See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01825655 - Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching Phase 4
Completed NCT01236859 - Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus N/A
Completed NCT00782054 - Evaluation of Post Burn Rehabilitation Population for Itch Control Phase 4
Completed NCT04999787 - A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus Phase 2
Recruiting NCT04256759 - Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Phase 2
Completed NCT04337073 - The Effect of Propofol on Dexamethasone-induced Perineal Pruritus Early Phase 1
Completed NCT04415034 - Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
Active, not recruiting NCT05525520 - Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis Phase 2
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT04399525 - Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin. N/A
Recruiting NCT02432508 - Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis N/A
Completed NCT02653703 - L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain N/A
Completed NCT01232985 - Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults Phase 2
Not yet recruiting NCT00577967 - Gabapentin - A Solution to Uremic Pruritus? N/A
Recruiting NCT06120907 - Swiss Itch Registry
Recruiting NCT04589429 - Adding Nalbuphine for Control of Intrathecal Morphine Pruritus Phase 2
Completed NCT03322137 - Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris Phase 2